C2 PHARMA's Upcoming Launch of Oxybuprocaine Hydrochloride

C2 PHARMA, a global provider of ophthalmic and niche active pharmaceutical ingredients (APIs), has launched its latest API, Naphazoline Hydrochloride. The validation campaign for Naphazoline HCL was completed in June 2024. A Certificate of Suitability (CEP) is under approval while the US-Drug Master File (US-DMF) is planned for submission by November 2024 and the API dossier for Brazil (DIFA) in December 2024.

As the global leader in Ophthalmic APIs, C2 PHARMA was asked to participate in Pharmasource’s buyer guide focused on Ophthalmics.

C2 PHARMA the global leader in manufacturing and supplying ophthalmic and niche active pharmaceutical ingredients (APIs), proudly announces the approval of a Certificate of Suitability (CEP) for Tropicamide by the European Directorate for the Quality of Medicines and Health Care (EDQM). This is the first Tropicamide CEP for a European-based company, allowing C2 PHARMA to make the API commercially accessible to customers globally.

C2P receives the approval of a Certificate of Suitability (CEP) for Tropicamide by the European Directorate for the Quality of Medicines and Health Care (EDQM).

C2 Pharma is excited to announce the upcoming launch of their new Ophthalmic API, Oxybuprocaine Hydrochloride. To learn more check out the full press release.

C2 PHARMA has expanded their API portfolio global access with new regulatory submissions and approvals, a pending new product launch and have signed on a new CMO, SMS Lifesciences. 

C2 PHARMA has added a new ophthalmic API to their portfolio, Naphazoline Hydrochloride. GMP samples are ready for customers worldwide.

Press release about C2 PHARMA's affiliate company Logistics4PHARMAs move and expansion of their GDP Bonded Warehouse to Kelsterbach, Germany.

Your API Manufacturing Partner and Affiliate companie.

Get to know a bit about why you should work with us and what we have to offer.

C2 Pharma receives the European Directorate for the Quality of Medicines and Healthcare second Certificate of Suitability for Cyclopentolate Hydrochloride, a significant achievement for our dedicated team. 

C2 PHARMA is a European pharmaceutical group established in 2014.

It manufactures and distributes active pharmaceutical ingredients

(APls) and complex chemical compounds obtained from synthetic and

natural origins. C2 PHARMA is today the global leader in ophthalmic APIs.

As the global leader in Ophthalmic APIs, C2 PHARMA was asked to participate in Pharmasource’s buyer guide focused on Ophthalmics. We go to show our expertise and share a bit about our company and product portfolio. 

 A quick portfolio review of what we have to offer as your global leader in Ophthalmic APIs.

PharmaSource's Supplier Spotlight podcast series featuring Senior Manager of Business Development Serge Tarabay talk about C2 PHARMA's rise to becoming the Global Leader in Ophthalmic APis. 

Press release covering our approval by the CDE of a C-DMF for Digoxin, becoming China’s only European supplier of this API. The approval covers both digoxin and digoxin micronized, and it supports different dosage forms, i.e., oral and injectable drug product formulations.

This article highlights the power of internal change for a greener future. From packaging to transportation, every logistics company has the opportunity to make a difference, and Logistics4Pharma's Head of Supply Chain & Finance and Head of Operations and Customer Service give their expertise and opinions on how to become greener for the future of pharmaceutical logistics.

A featured interview with CEO of C2 PHARMA, Andrew Badrot, where he discusses his journey to starting the company and its affiliates, along with the importance of quality and quality relationships.

A press release covering the launch of affiliate ASM Research Chemicals new service development, "Devpacks". The service was developed and optimized across ten core partners to establish a standardized and robust dataset of development process steps. Now fully optimized and streamlined, the DevPack service is commercially available to help overcome resource bottlenecks and streamline API research, development, troubleshooting, and scale-up activities.